Hur JY - Search Results

1

p27 Cell Cycle Inhibitor and Survival in Luminal-Type Breast Cancer: Gene Ontology, Machine Learning, and Drug Screening Analysis.

Park IA, Noh YK, Min KW, Kim DH, Lee JY, Son BK, Kwon MJ, Han MH, Hur JY, Pyo JS. Park IA, et al. Among authors: hur jy. J Breast Cancer. 2024 Oct;27(5):305-322. doi: 10.4048/jbc.2024.0107. Epub 2024 Sep 4. J Breast Cancer. 2024. PMID: 39344410 Free PMC article.

2

CLDN18: Clinical, Pathological, and Genetic Signatures with Drug Screening in Gastric Adenocarcinoma.

Hur JY, Min KW, Noh YK, Won YW, Yeo Y, Kim DH, Son BK, Kwon MJ, Pyo JS. Hur JY, et al. Curr Med Chem. 2024 Apr 18. doi: 10.2174/0109298673288604240408065715. Online ahead of print. Curr Med Chem. 2024. PMID: 38639279

3

High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer.

Kim Y, Byeon SJ, Hur J, Lee K, Kim D, Ahn JH, Lee SH, You WK, Kim ST, Park SH, Kang WK, Kim KM, Lee J. Kim Y, et al. J Cancer. 2019 Jun 2;10(14):3172-3178. doi: 10.7150/jca.30257. eCollection 2019. J Cancer. 2019. PMID: 31289587 Free PMC article.

4

Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer.

Hur JY, Lee HY, Chang HJ, Choi CW, Kim DH, Eo WK. Hur JY, et al. J Cancer. 2020 Feb 25;11(10):2800-2807. doi: 10.7150/jca.41122. eCollection 2020. J Cancer. 2020. PMID: 32226498 Free PMC article.

5

Clinical significance of C-Reactive Protein to Lymphocyte Count Ratio as a prognostic factor for Survival in Non-small Cell Lung Cancer Patients undergoing Curative Surgical Resection.

Hwang JJ, Hur JY, Eo W, An S, Kim DH, Lee S. Hwang JJ, et al. Among authors: hur jy. J Cancer. 2021 May 27;12(15):4497-4504. doi: 10.7150/jca.58094. eCollection 2021. J Cancer. 2021. PMID: 34149913 Free PMC article.

6

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea.

Lee JY, Kwon JH, Hur JY, Yi JH, Lee JH, Cho H, Do YR, Jo JC, Kang HJ, Koh Y, Lee WS, Lim SN, Yoon SE, Kim SJ, Lee JO. Lee JY, et al. Among authors: hur jy. Cancer Res Treat. 2024 Apr;56(2):681-687. doi: 10.4143/crt.2023.1042. Epub 2023 Nov 10. Cancer Res Treat. 2024. PMID: 37946408 Free PMC article.

7

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study.

Hur JY, Kim Y, Kwon GY, Kang M, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Lee SJ, Park SH. Hur JY, et al. Cancer Res Treat. 2019 Oct;51(4):1269-1274. doi: 10.4143/crt.2018.604. Epub 2019 Jan 9. Cancer Res Treat. 2019. PMID: 30653744 Free PMC article.

8

Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.

Park JH, Park I, Kim IH, Hur JY, Hwang I, Kim C, Kim HJ, Maeng CH, Park K, Lee MY, Lee HJ, Jung JY, Keam B, Park SH, Lee JL. Park JH, et al. Among authors: hur jy. Curr Probl Cancer. 2022 Jun;46(3):100848. doi: 10.1016/j.currproblcancer.2022.100848. Epub 2022 Mar 8. Curr Probl Cancer. 2022. PMID: 35344842

9

Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib.

Choi JH, Hur JY, Won YW. Choi JH, et al. Among authors: hur jy. Cancer Res Treat. 2023 Apr;55(2):704-705. doi: 10.4143/crt.2022.1524. Cancer Res Treat. 2023. PMID: 36652902 Free PMC article. No abstract available.

10

Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.

Hur JY, Kim JY, Ahn JS, Im YH, Lee J, Kwon M, Park YH. Hur JY, et al. Cancers (Basel). 2020 May 21;12(5):1306. doi: 10.3390/cancers12051306. Cancers (Basel). 2020. PMID: 32455662 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters